Alpha-2 Adrenergic Agonists for Solid Tumor Treatment

The patent employs small molecule alpha-2 adrenergic receptor agonists that can be administered systemically and act temporarily to inhibit tumor growth. These short-acting compounds are metabolized and eliminated from the body, requiring repeated dosing but avoiding the complexity of surgical procedures or long-term immunotherapy protocols. The compounds serve as simple, disposable therapeutic agents that provide reliable tumor control through their pharmacological action on adrenergic receptors in the tumor microenvironment.

The patent separates the assessment process into two distinct stages: initial in vitro screening for compound identification, followed by in vivo validation in immunocompetent animal models. This segmentation allows high-throughput initial screening to identify promising compounds, while subsequent in vivo studies in immunocompetent mice capture the immune response component that in vitro systems cannot assess. The two-stage approach efficiently balances screening productivity with reliable immune response evaluation.

The patent employs alpha-2 adrenergic receptor agonists as neoadjuvant therapy to shrink tumors before surgical resection. By administering these compounds prior to surgery, the treatment reduces tumor burden and may eliminate micrometastatic disease, thereby increasing the effectiveness of the subsequent surgical intervention and potentially reducing the need for additional adjuvant treatments. This preliminary pharmacological action optimizes the overall treatment outcome while reducing the time patients spend undergoing multiple sequential therapies.